QURE - uniQure N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

31.31

+0.48 (+1.56%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	30.83
Open	30.94
Bid	0.00 x 900
Ask	0.00 x 1400
Day's Range	30.93 - 31.52
52 Week Range	4.90 - 33.33
Volume	284,500
Avg. Volume	381,446

Market Cap	1.157B
Beta	-0.28
PE Ratio (TTM)	N/A
EPS (TTM)	-2.94
Earnings Date	May 30, 2017 - Jun 2, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	43.20

Trade prices are not sourced from all markets

All

News

Press Releases

CNBC Videos24 days ago
Kensho's genetic engineering index
Kensho genetic engineering index has jumped 45% in the past year. It's top components, Uniqure NV, Sangamo Therapeutics and Abeona Therapeutics.
Benzinga11 hours ago
Uniqure Notches Bullish Initiation On Gene Therapy Prospects
Uniqure NV (NASDAQ: QURE ) has managed to win the seal of approval from Wells Fargo Securities due to its gene therapy pipeline candidates that target multiple diseases. The Analyst Analyst Jim Birchenough ...
GlobeNewswire3 days ago
uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
--Preclinical Data Presented at the American Society of Gene & Cell Therapy Annual Meeting in Chicago--. LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 18, 2018-- uniQure N.V., a leading gene therapy ...
TheStreet.com7 days ago
3 Cutting-Edge Biotech Stocks That Can Double in Value
In fact, all three of these shares only show 100% buy ratings and huge upside potential of over 100%. Learn more about retirement planning via TheStreet's newest service. Shares are too cheap right now, argues top Oppenheimer analyst Hartaj Singh.
Motley Fool11 days ago
3 High-Growth Stocks That Could Soar
Two e-commerce specialists head up this list of promising investment ideas.
GlobeNewswire14 days ago
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 07, 2018-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia ...
Motley Fool17 days ago
2 Cheap Growth Stocks to Buy Right Now
These two clinical-stage biotechs could be absolute steals at current levels.
GlobeNewswire18 days ago
uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 02, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive heart failure, today announced the pricing of its underwritten public offering of 4,500,000 of its ordinary shares at a public offering price of $28.50 per share. The gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by uniQure, are expected to be $128,250,000. All ordinary shares to be sold in the offering are being sold by uniQure.
GlobeNewswire19 days ago
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive heart failure, today announced that it has commenced an underwritten public offering of 4,000,000 of its ordinary shares. All ordinary shares to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 600,000 additional ordinary shares at the public offering price, less underwriting discounts and commissions.
GlobeNewswire21 days ago
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 to be Featured in Oral Presentation. LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 30, 2018-- uniQure N.V., a leading gene ...
Associated Press21 days ago
UniQure: 1Q Earnings Snapshot
On a per-share basis, the Amsterdam-based company said it had a loss of 59 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
GlobeNewswire21 days ago
uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress
~Patient enrollment expected to begin ahead of schedule in dose-confirmation study for AMT-061 and pivotal study on track to commence in third quarter of 2018. ~IND filing for AMT-130 in Huntington’ s ...
GlobeNewswire24 days ago
uniQure Announces to Present at Multiple Conferences in May
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 27, 2018-- uniQure N.V., a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical and ...
GlobeNewswire25 days ago
uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting
~Mutant Huntingtin Protein Reduced by a Median of 68% in the Deep Structures of the Brain and a Median of 47% in the Frontal Cortex at 6 Months in a Large Diseased Animal Model~. LEXINGTON, Mass. and AMSTERDAM, ...
Benzinga27 days ago
Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure
Uniqure NV (NASDAQ: QURE ) struck all-time highs last week and continued to linger near its peak value. One analyst projects 61-percent upside and considers the equity a top pick in 2018. The Rating Chardan ...
Market Realistlast month
An In-Depth Look at UniQure’s Cash Flows and Valuation
UniQure (QURE) spent $64.2 million in operating activities in fiscal 2017 compared to $72.1 million in fiscal 2016. In fiscal 2017, UniQure spent $5.5 million in investing activities compared to $17.1 million in fiscal 2016. In fiscal 2016, UniQure spent $13.4 million on this facility, while in 2017, it spent $3 million.
Market Realistlast month
Insights into UniQure’s Financial Performance
The major sources of UniQure’s (QURE) revenues are from licensing revenue and collaboration revenue. In fiscal 2017, its license revenue from related parties was $4.1 million compared with $3.9 million in fiscal 2016. A major part of UniQure’s collaboration revenues comes from its collaboration agreement with Bristol-Myers Squibb (BMY) entered into in 2015.
Market Realistlast month
UniQure’s Promising Research Pipeline
UniQure’s (QURE) adeno-associated virus technology platform and its proprietary insect cell-based manufacturing capabilities provide the company with the potential to reduce development risk, cost, and time to market.
Market Realistlast month
Analyst Ratings for UniQure and Its Peers in April 2018
UniQure (QURE) is a leading company in the field of gene therapy. It has a focused pipeline of innovative gene therapies developed both internally and through collaboration for cardiovascular diseases. It has established clinical proof of concept for its lead indication, hemophilia B, and has achieved preclinical proof of concept in Huntington’s disease.
Zackslast month
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Market Realistlast month
Analysts Rate Voyager Therapeutics and Its Peers in April
Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.
Simply Wall St.last month
How Do Analysts See uniQure NV. (NASDAQ:QURE) Performing In The Next Couple Of Years?
In December 2017, uniQure NV. (NASDAQ:QURE) released its latest earnings announcement, which confirmed that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below,Read More...
GlobeNewswirelast month
Report: Developing Opportunities within Consol Energy, 51job, MakeMyTrip, LyondellBasell Industries N.V, Golden Ocean Group, and uniQure N.V — Future Expectations, Projections Moving into 2018
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Benzinga2 months ago
Janney: Buy The Dip In Uniqure
Uniqure NV (NASDAQ: QURE ) shares slid 22 percent in two weeks with no fundamental changes, prompting a Janney analyst to recommend buying the dip. The Analyst Janney analyst Yun Zhong reiterated a Buy ...
GlobeNewswire2 months ago
Report: Developing Opportunities within Itau Unibanco Banco Holding SA, NantHealth, Southern First Bancshares, uniQure N.V., Ascendis Pharma A/S, and National General — Future Expectations, Projections Moving into 2018
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...